Inozyme Pharma (INZY) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

INZY Inozyme Pharma

Watchlist

2.640
-0.170-6.05%

Close Nov 25 16:00 ET

2.920
+0.280+10.61%

Pre 07:03 ET

169.59MMarket Cap-1703P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Simply Wall StNov 16 09:25 ET
Here's Why Inozyme Pharma (INZY) Is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Zacks Nov 13 08:45 ET
Inozyme Pharma to Present at Upcoming Investor Conferences
GlobeNewswireNov 11 08:30 ET
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsNov 8 10:37 ET · Ratings
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsNov 6 06:33 ET · Ratings
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Moomoo NewsNov 5 14:33 ET · Ratings

Comments

Jaguar8

Oct 24 12:15

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
Inozyme Pharma (INZY) announced positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. The trial demonstrated that INZ-701 significantly increased plasma pyrophosphate (PPi) levels in patients, with levels rising into the normal range by week 3 of the four-week dosing schedule. The drug was well-...

Jaguar8

Jul 25 07:31

NEWS

$Inozyme Pharma (INZY.US)$
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
Inozyme Pharma (Nasdaq: INZY) has published preclinical data in the journal Cells, supporting the potential of INZ-701, their lead ENPP1 enzyme replacement therapy (ERT) candidate, to treat a broad range of rare diseases affecting bone health and blood vessel function. The study demonstrates IN...

Jaguar8

May 23 07:33

$Inozyme Pharma (INZY.US)$
NEWS
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS)...

Meltyy

Jan 4 01:15

$XBI: Biotech Sector's Potential Outperformance in 2024, Especially Pre-Election Volatility in 1H

$SPDR S&P Biotech ETF (XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...